Open AccessProgression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021
Author(s) -
Brittany Smith,
Andrew B. Janowski,
Arim C. Fremont,
Lucas J. Adams,
Ya-Nan Dai,
Christopher W Farnsworth,
Ann M. Gronowski,
Stephen M. Roper,
David Wang,
Daved H. Fremont
Publication year - 2021
Publication title -
msphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.749
H-Index - 39
ISSN - 2379-5042
DOI - 10.1128/msphere.00450-21
Subject(s) - seroprevalence , medicine , pandemic , covid-19 , vaccination , demography , outbreak , pediatrics , antibody , serology , virology , immunology , disease , infectious disease (medical specialty) , sociology
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seropositivity was assessed for 3,066 individuals visiting hospitals in St. Louis, Missouri, during July 2020, November 2020, or January 2021. Seropositivity in children increased from 5.22% in July to 21.16% in January. In the same time frame, seropositivity among adults increased from 4.52% to 19.03%, prior to initiation of mass vaccination. IMPORTANCE This study determined the percentage of children and adult samples from the St. Louis metropolitan area in Missouri with SARS-CoV-2 antibodies during three collection periods spanning July 2020 to January 2021. By January 2021, 20.68% of the tested individuals had antibodies. These results show the evolution of the SARS-CoV-2 pandemic in St. Louis, Missouri, and provide a snapshot of the extent of infection just prior to the start of mass vaccination.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom